Lilly three-year tirzepatide results show sustained weight loss, diabetes benefits

Indianapolis - April 2016: Eli Lilly and Company IX

jetcityimage/iStock Editorial via Getty Images

  • More detailed results from Eli Lilly’s (NYSE:LLY) three-year, phase 3 SURMOUNT-1 study showed that tirzepatide, the active ingredient in its obesity and type 2 diabetes meds, respectively, Wegovy and Ozempic, led to sustained weight loss and diabetes benefits.
  • After three

Leave a Reply

Your email address will not be published. Required fields are marked *